Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SC100 is a proprietary botanical supplement developed by Genescient Corporation, designed to promote life extension and enhance stress resistance. It consists of a complex mixture of herbal extracts that are predicted to modulate the expression of several key genes and pathways involved in the aging process, including the mechanistic target of rapamycin (mTOR), nitric oxide synthase (NOS), nuclear factor kappa B (NF-kappaB), and vascular endothelial growth factor (VEGF). Research conducted in *Drosophila* models has shown that SC100 can stabilize midlife mortality rates and significantly extend maximum lifespan. While it is commercially available as a dietary supplement under the brand name Stem Cell 100, versions of the formulation have also been evaluated in double-blind, placebo-controlled human clinical trials to study its effects on aging and stress resistance.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on SC100.